Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns for investors and this year it's also up around 20% as there's still ample bullishness around the business. The company is a leader in cystic fibrosis treatments with an eye for more growth and diversification in the long run.

Does Vertex have the potential to be a millionaire-making investment going forward?

The challenge for Vertex Pharmaceuticals will be to keep its growth rate strong. For the quarter ending June 30, the company's sales totaled $2.5 billion and were up 14% year over year. That revenue comes mainly from cystic fibrosis products, specifically Trikafta/Kaftrio, which generated over $2.2 billion.

Continue reading

Source Fool.com